Hematologic Oncology

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

John M. Pagel, MD, PhD, discusses challenges with autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

The approval of tazemetostat has expanded the portfolio of treatment options for relapsed/refractory follicular lymphoma, a disease for which new agents are needed because patients do not uniformly derive benefit from available therapies.

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.

John M. Pagel, MD, PhD, discusses the importance of screening patients for double-hit and triple-hit diffuse large B-cell lymphoma.

The FDA’s Oncologic Drugs Advisory Committee voted 8 to 2 in favor of approving remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.

The FDA has granted a priority review designation to a new drug application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior anti-CD20–based treatment.

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

John M. Pagel, MD, PhD, discusses current treatment approaches in frontline and relapsed/refractory DLBCL and provides insight on some of the agents that are generating excitement in the relapsed/refractory setting.

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

The American Society of Hematology has published new evidence-based guidelines to support older patients with acute myeloid leukemia and their health care providers in guiding treatment decisions.